Things are changing fast at ADC Therapeutics, where CEO Ameet Mallik has tapped a strategy chief shortly after taking the post.
A month after stepping into the role, Mallik is bringing in David Gilman to lead business and strategy at the Zynlonta maker and antibody-drug conjugate specialist.
Effective next month, Gilman will report to Mallik as the company's new chief business and strategy officer.
Gilman's 25 years of industry experience includes a yearlong stint at Novartis as global head of portfolio strategy and business development for Novartis Oncology, where Mallik worked as well. The new CEO snatched Gilman up from ClearView Healthcare Partners, a global strategy and consulting firm he had been at since 2019.
Gilman’s ClearView bio says his areas of speciality include oncology, immunology, infectious and rare diseases. He’s also spent time teaching life sciences to business students as well as teaching business to medical students.
At ADC, Gilman will be responsible for all business development and portfolio strategy efforts on a global scale.
The company is currently evaluating Cami (camidanlumab tesirine) in a phase 2 trial for relapsed or refractory Hodgkin lymphoma and a separate phase 1b trial for various advanced solid tumors.
ADC Therapeutics also has an FDA approval for its CD19-directed ADC Zynlonta, which treats relapsed or refractory diffuse large B-cell lymphoma after at least two lines of systemic therapy.